Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase III Trial of Anaplastic Glioma Without 1p/19q LOH (CATNON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00626990
Recruitment Status : Active, not recruiting
First Posted : February 29, 2008
Last Update Posted : February 3, 2021
Sponsor:
Collaborators:
NCIC Clinical Trials Group
Radiation Therapy Oncology Group
Medical Research Council
Cooperative Trials Group for Neuro-Oncology
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2024
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.